285 related articles for article (PubMed ID: 30920776)
1. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review.
Anker MS; Holcomb R; Muscaritoli M; von Haehling S; Haverkamp W; Jatoi A; Morley JE; Strasser F; Landmesser U; Coats AJS; Anker SD
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):22-34. PubMed ID: 30920776
[TBL] [Abstract][Full Text] [Related]
2. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
3. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
4. Achieving orphan designation for placental insufficiency: annual incidence estimations in Europe.
Spencer R; Rossi C; Lees M; Peebles D; Brocklehurst P; Martin J; Hansson SR; Hecher K; Marsal K; Figueras F; Gratacos E; David AL;
BJOG; 2019 Aug; 126(9):1157-1167. PubMed ID: 30576053
[TBL] [Abstract][Full Text] [Related]
5. Cancer cachexia: an orphan with a future.
Lainscak M; Rosano GMC
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):3-5. PubMed ID: 30920780
[No Abstract] [Full Text] [Related]
6. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016.
von Haehling S; Anker MS; Anker SD
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):507-509. PubMed ID: 27891294
[TBL] [Abstract][Full Text] [Related]
7. [The legal regulation of life cycle of orphan pharmaceuticals].
Gildeyeva GN; Kartavtsova TV
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
[TBL] [Abstract][Full Text] [Related]
8. Drugs for rare disorders.
Cremers S; Aronson JK
Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
[TBL] [Abstract][Full Text] [Related]
9. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
10. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
Boyce M; Thomsen L
Scand J Gastroenterol; 2015 May; 50(5):550-9. PubMed ID: 25665655
[TBL] [Abstract][Full Text] [Related]
11. [Hope for patients with rare diseases--"orphan" drugs].
Kuzelová M; Kubácková K; Palágyi M; Smíd M
Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
[TBL] [Abstract][Full Text] [Related]
12. Italian cancer figures, report 2014: Prevalence and cure of cancer in Italy.
AIRTUM Working Group
Epidemiol Prev; 2014; 38(6 Suppl 1):1-122. PubMed ID: 25759295
[TBL] [Abstract][Full Text] [Related]
13. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
14. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
Murakami M; Narukawa M
Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
[TBL] [Abstract][Full Text] [Related]
15. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
Hirota S; Yamaguchi T
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
[TBL] [Abstract][Full Text] [Related]
16. Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU).
Casali PG; Trama A
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220947
[TBL] [Abstract][Full Text] [Related]
17. Cancer cachexia update in head and neck cancer: Definitions and diagnostic features.
Couch ME; Dittus K; Toth MJ; Willis MS; Guttridge DC; George JR; Barnes CA; Gourin CG; Der-Torossian H
Head Neck; 2015 Apr; 37(4):594-604. PubMed ID: 24415363
[TBL] [Abstract][Full Text] [Related]
18. Kidney cachexia or protein-energy wasting in chronic kidney disease: facts and numbers.
Koppe L; Fouque D; Kalantar-Zadeh K
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):479-484. PubMed ID: 30977979
[TBL] [Abstract][Full Text] [Related]
19. The European Union Policy in the Field of Rare Diseases.
Moliner AM; Waligora J
Adv Exp Med Biol; 2017; 1031():561-587. PubMed ID: 29214592
[TBL] [Abstract][Full Text] [Related]
20. Cachexia: prevalence and impact in medicine.
Tan BH; Fearon KC
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):400-7. PubMed ID: 18541999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
